Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
Michael Volkov describes Novartis as “lucky” for a relatively positive outcome despite its 2016 SEC enforcement action in China and its culture of non-compliance, which could have led to assignment of an independent corporate compliance monitor and a higher penalty.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every Brief, six days a week.